Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Hansoh Pharma Now Said to Plan $3 Billion IPO

publication date: Jan 6, 2016
According to The Wall Street Journal, Jiangsu Hansoh Pharma is planning to raise over $3 billion in an IPO on the Hong Kong market, which would be record amount for a pharma IPO in Hong Kong. One month ago, it was reported that Hansoh would seek $1.5 billion in an initial offering, implying that the reports are partly rumor. The company may complete a filing for the transaction as early as March, which will shed more light on Hansoh and its IPO. The actual transaction is scheduled for Q3 of this year More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital